Brief: Gain Therapeutics Announces Positive Topline Data In Patient-Derived IPSC Study Evaluating Star Compounds As Treatment For Gaucher And Parkinson’s Disease
08/09/2021 12:34
Sept 8 (Reuters) - Gain Therapeutics Inc GANX.O :
* GAIN THERAPEUTICS, INC. ANNOUNCES POSITIVE TOPLINE DATA IN
PATIENT-DERIVED IPSC STUDY EVALUATING STAR COMPOUNDS AS
A TREATMENT FOR GAUCHER AND PARKINSON’S DISEASE
* GAIN THERAPEUTICS - RESULTS DEMONSTRATE INCREASE IN GCASE
PROTEIN LEVELS WITH TRANSPORT TO LYSOSOMES
* GAIN THERAPEUTICS - RESULTS DEMONSTRATE DECREASE OF
GLUCOSYLCERAMIDE, Α-SYNUCLEIN-P129 LEVELS
* GAIN THERAPEUTICS INC - IND-INITIATING STUDY PLANNED FOR
Q4'21
Source text for Eikon: ID:nGNX6s2FDD
Further company coverage: GANX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gain Therapeutics
See all newsU.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Gain Therapeutics climbs on narrower-than-expected quarterly loss
Gain Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall